Fatores de risco associados a náuseas e vômitos induzidos por quimioterapia antineoplásica
DOI:
https://doi.org/10.11606/s1518-8787.2020054002178Palavras-chave:
Antineoplásicos, efeitos adversos, Náusea, Vômito, prevenção & controle, Antieméticos, Neoplasias, terapia. Estudos de CoortesResumo
OBJETIVO: Estimar a incidência e avaliar os fatores de risco para náuseas e vômitos induzidos por antineoplásicos com alto e moderado potencial emético em pacientes adultos, no primeiro ciclo de tratamento. MÉTODOS: Estudo de coorte prospectiva, com 269 adultos acompanhados durante o primeiro ciclo de quimioterapia antineoplásica. A incidência de náuseas e vômitos foi avaliada na fase aguda (0–24 horas), na fase tardia (24 horas–5º dia) e na fase total (0–5º dia). RESULTADOS: 152 pacientes foram submetidos a quimioterápico com alto potencial emético e 117 a moderado potencial emético. A frequência relativa de náuseas foi maior quando comparada à de vômitos na fase aguda (p < 0,001) e na fase tardia (p < 0,001). Os fatores de risco identificados foram: faixa etária ≤ 49 anos (odds ratio = 0,47; IC95% 0,23–0,95) e 50–64 anos (odds ratio = 0,45; IC95% 0,23–0,87), uso de tabaco (odds ratio = 0,35; IC95% 0,14–0,88) e alto potencial emético dos quimioterápicos (odds ratio 0,55; IC95% 0,31–0,95). CONCLUSÃO: A incidência de náuseas foi maior do que a de vômitos, e na fase tardia os efeitos adversos foram mais frequentes. Os resultados sugerem que os fatores de risco para náuseas e vômitos induzidos por quimioterapia são o tabaco, a idade (adultos jovens) e o alto potencial emético do quimioterápico.
Referências
Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42-6. https://doi.org/10.4103/0971-5851.177015
Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Therap Adv Gastroenterol. 2016;9(1):98-112. https://doi.org/10.1177/1756283X15618131
Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, et al. Prediction of chemotherapyinduced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer. 2018;26(8):2911-8. https://doi.org/10.1007/s00520-018-4120-6
Schwartzberg LS, Rugo HS, Aapro MS.. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2015;13(3 Suppl 3):3-14.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia Consensus Conference. Ann Oncol. 2010;21 Suppl 5:v232-43. https://doi.org/10.1093/annonc/mdq194
Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011;19(6):843-51. https://doi.org/10.1007/s00520-010-0915-9
Associação Brasileira de Cuidados Paliativos. Consenso brasileiro de náuseas e vômitos em cuidados paliativos. Rev Bras Cuid Paliat. 2011 [cited 2015 Jan 10];3(3 Supl 2):1-26. Available from: http://revistaonco.com.br/associacao-brasileira-de-cuidados-paliativos-apresenta-1oconsenso- brasileiro-de-nauseas-e-vomitos/
Moradian S, Howell D. Prevention and management of chemotherapy-induced nausea and vomiting. Int J Palliat Nurs. 2015;21(5):216, 218-24. https://doi.org/10.12968/ijpn.2015.21.5.216
Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-8. https://doi.org/10.1200/JCO.2006.05.6382
Dinis J, Wisniewski T, Moreira A, Raposo J, Ma L, Burke TA. Chemotherapy-induced nausea and vomiting in Portugal: incidence versus healthcare provider estimations and effect on quality of life. Therapy. 2009;6(4):595-602.
Caiaffa WT, Almeida MCM, Oliveira CDL, Friche AAL, Matos SG, Dias MAS, et al. The urban environment from the health perspective: the case of Belo Horizonte, Minas Gerais, Brazil. Cad Saude Publica. 2005;21(3):958-67. https://doi.org/10.1590/S0102-311X2005000300032
Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, et al. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer. 2015;23(1):263-72. https://doi.org/10.1007/s00520-014-2373-2
Rha YS, Park Y, Song SK, Lee CE, Lee J. Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. Support Care Cancer. 2016;24(8):3379-89. https://doi.org/10.1007/s00520-016-3146-x
Hilarius DL, Kloeg PH, Wall E, Heuvel JJG, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20(1):107-17. https://doi.org/10.1007/s00520-010-1073-9
Figueiredo FWS, Almeida TCC, Schoueri JHM, Luisi C, Adami F. Association between primary care coverage and breast cancer mortality in Brazil. PLoS One. 2018;13(8):e0200125. https://doi.org/10.1371/journal.pone.0200125
Figueiredo FWS, Adami F. Income inequality and mortality owing to breast cancer: evidence from Brazil. Clin Breast Cancer. 2018;18(4):e651-8. https://doi.org/10.1016/j.clbc.2017.11.005
Renna Junior NL, Silva GAE. Late-stage diagnosis of breast cancer in Brazil: analysis of data from hospital-based cancer registries (2000-2012). Rev Bras Ginecol Obstet. 2018;40(3):127-36. https://doi.org/10.1055/s-0038-1624580
Farrell C, Brearley SG, Pilling M, Molassiotis A. The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support Care Cancer. 2013;21(1):59-66. https://doi.org/10.1007/s00520-012-1493-9
Lete I, Allué J. The effectiveness of ginger in the prevention of nausea and vomiting during pregnancy and chemotherapy. Integr Med Insights. 2016;11:11-7.
https://doi.org/10.4137/IMI.S36273
Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol. 2008;26(34):5618-29. https://doi.org/10.1200/JCO.2007.15.9053
Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2014;47(5):839-48.e4 https://doi.org/10.1016/j.jpainsymman.2013.06.012
Kaushal P, Atri R, Soni A, Kaushal V. Comparative evaluation of tripletic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience. 2015;9:567. https://doi.org/10.3332/ecancer.2015.567
Schwartzberg L, Harrow B, Lal LS, Radtchenko J, Lyman GH. Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. Am Health Drug Benefits. 2015;8(5):273-82.
Mizuno M, Hiura M, Kikkawa F, Numa F, Yaegashi N, Narahara H, et al. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan. Gynecol Oncol. 2016;140(3):559-64. https://doi.org/10.1016/j.ygyno.2015.12.029
Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving Adriamycin cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19(6):807-13. https://doi.org/10.1007/s00520-010-0899-5
Esra YE, Aziz Y, Zeki U, Gülsah G, Mert B, Yesim E, et al. Is chemotherapy-induced nausea and vomiting lower in smokers? Int J Clin Pharmacol Ther. 2011;49(12):709-12.
Peppone LJ, Mustian KM, Morrow GR, Dozier AM, Ossip DJ, Janelsins MC, et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist. 2011;16(12):1784-92. https://doi.org/10.1634/theoncologist.2011-0169
Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard - of care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18(9):1171-7. https://doi.org/10.1007/s00520-009-0737-9
Zook DJ, Yasko JM. Psychologic factors: their effect on nausea and vomiting experienced by clients receiving chemotherapy. Oncol Nurs Forum. 1983;10(3):76-81.
Sheikhi MA, Ebadi A, Talaeizadeh A, Rahmani H. Alternative methods to treat nausea and vomiting from cancer chemotherapy. Chemother Res Pract. 2015;2015:818759. https://doi.org/10.1155/2015/818759
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2020 Revista de Saúde Pública
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
